中国专家关于肝细胞癌新辅助和转化疗法的共识:2023年更新

Xinyu Bi1, Haitao Zhao2, Hong Zhao1

  • 1Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Liver cancer
|April 21, 2025
PubMed
概括

新辅助和转化疗法可以改善肝细胞癌 (HCC) 患者的外科切除率. 这个更新的2023年共识提供了指导,以加强治疗策略和减少中等到高级HCC的复发.